Compounds for treating spinal muscular atrophy

A compound of formula (I):

• wherein:
• X is N or CR3;
• Y is N or CR4;
• with the proviso that not both X and Y are N;
• A is a bicyclic 9-membered heteroaryl comprising two or three heteroatoms independently selected from N or O, wherein A can be optionally substituted with one, two or three R5;
• B is a saturated or partially unsaturated mono- or bicyclic 4 to 9-membered heterocycloalkyl comprising one or two ring nitrogen atoms, the remaining ring atoms being carbon, wherein B can be optionally substituted with one, two or three R6;
• R1 is hydrogen, halo, C1-7-alkyl, C1-7-haloalkyl, C1-7-alkoxy or C1-7-haloalkoxy;
• R2 is hydrogen, halo, C1-7-alkyl, C1-7haloalkyl, C1-7-alkoxy or C1-7-haloalkoxy;
• R3 is hydrogen, halo, C1-7-alkyl, C1-7-haloalkyl, C1-7-alkoxy or C1-7-haloalkoxy;
• R4 is hydrogen, halo, C1-7-alkyl, C1-7-haloalkyl, C1-7-alkoxy or C1-7-haloalkoxy;
• each R5 is independently selected from halo, cyano, C1-7-alkyl, C1-7-haloalkyl or C3-7-cycloalkyl;
• each R6 is independently selected from C1-7-alkyl, or two R6 together form a C2-7-alkylene;
• or a pharmaceutically acceptable salt thereof.